Business Wire

AIR Brings World-Leading Inhalation Product Portfolio to InterTabac, as Demand for Shisha Surges Among Business Owners

8.9.2025 09:00:00 EEST | Business Wire | Press release

Share

Advanced Inhalation Rituals (AIR), the world’s leading social inhalation business, will be showcasing its most comprehensive portfolio to date at this year’s InterTabac, the world’s leading trade fair for tobacco products and smoking accessories, taking place from 18 – 20 September 2025 in Dortmund, Germany.

From the heritage of Al Fakher, the world’s #1 shisha brand, to OOKA, AIR’s revolutionary charcoal-free shisha device, visitors to InterTabac will gain a first-hand look at how AIR is shaping the future of shisha. Visitors will be able to sample flavors, explore breakthrough technologies, and discover how our multi-category portfolio creates new opportunities for lounges, retailers, and distributors alike.

The shisha market is not only growing – it’s evolving rapidly. AIR’s research shows that nine in ten (90%) businesses expect to see demand for shisha increase over the next two years, with strong optimism across the major markets of the UAE, US, Spain and Germany.

Findings from AIR’s survey of 400 hospitality businesses across Spain, Germany, the US, and the UAE show that consumer expectations are shifting rapidly, with greater focus on health, sustainability, and premium experiences:

  • 87% now view sustainability and cleanliness as critical when selecting shisha solutions
  • 32% believe charcoal-free shisha improves air quality and customer comfort
  • 29% say adopting charcoal-free shisha solutions strengthens their reputation with eco-conscious guests
  • 27% believe it will help attract more health-conscious customers

In response, AIR has built a portfolio that directly reflects these shifting consumer demands. At InterTabac 2025, the company will unveil its most comprehensive range to date, including:

  • Al Fakher – The World’s #1 Shisha Brand
    • Signature Collection: Globally loved classics, proven performers in every market
    • Mixes: Single-flavor blends designed for endless customization
    • Crafted Mixes: Layered, expertly blended profiles by Al Fakher’s shisha masters
    • An exciting collaboration with an international icon and celebrity, featuring bold blends made to stand out
  • Al Fakher Nicotine Pouches
    • Tobacco-free, discreet, and infused with signature shisha flavors. Available in 6mg, 10mg, and 15mg strengths. Intertabac visitors will enjoy a first look at this range
  • Crown Switch by Al Fakher
    • A rechargeable pod system with switchable disposable pods, powered by Quantum Vape Technology™ for flavor-packed sessions
  • OOKA Pro
    • Revolutionary charcoal-free shisha devices for venues, with up to eight sessions on a single charge and a wide range of flavors

Stuart Brazier, CEO of AIR, commented: “InterTabac is the perfect stage to show how far AIR has come in the last two years. Across our portfolio, we’re redefining what shisha is today. While our approach remains deeply rooted in the social traditions at the heart of shisha, our focus on innovation is ensuring that we also give consumers and businesses what they increasingly expect around health, comfort, ease of use and sustainability.

“As the global appetite for shisha continues to grow, we’re proud to be leading the way in redefining what the experience looks like for the next generation. We are committed to helping our partners create cleaner, smarter, and more sustainable solutions that unlock real growth.”

A leading force in the industry, AIR is transforming the future of shisha. With advanced research, design and development capabilities in Dubai and production facilities in the UAE and Poland, AIR is scaling across categories to serve the evolving needs of lounges, retailers, and distributors worldwide.

Visitors to AIR’s stand at InterTabac (G10 and G06, Hall 8) will be able to experience the full multi-category portfolio first-hand, sample Al Fakher and OOKA flavors, and access exclusive trade offers.

Note to editors:

InterTabac is the world’s leading trade fair for tobacco products and smoking accessories. 14,500 visitors attended in 2024 and the 2025 event takes place from September 18-20 in Dortmund. More information is here: https://www.intertabac.de/en/.

About the research

  • 400 Business Owners (aged 18+) at hospitality businesses that sell shisha across Spain, Germany, US, and UAE between 19.02.2025 - 24.02.2025 by Censuswide.

Censuswide abides by and employs members of the Market Research Society and follows the MRS code of conduct and ESOMAR principles. Censuswide is also a member of the British Polling Council.

About AIR

AIR is the market leader in the $19 billion global shisha market, with an aim to provide superior physical, emotional, and mental benefits through inhalation.

Launched in 1999 and headquartered in Dubai, the business has a multinational presence in over 100 countries across the UAE, Europe, North America, India, and Africa. AIR holds 47% of the shisha category market share in the markets it is present in and is the leading business in a market set to grow to $22 billion in 2026. Its portfolio of companies includes Al Fakher, the world’s leading shisha brand; Hookah-Shisha.com, the world’s number one e-commerce platform for hookahs and shisha; OOKA, the world’s first charcoal-free shisha device, among others. AIR’s science program, conducted in partnership with independent accredited laboratories, enables the development of innovative products that combine centuries of tradition with cutting edge innovation to minimize harm and maximize enjoyment for millions around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250907187544/en/

Contacts

Media contact
Boldspace
airglobal@boldspace.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye